menu
  • Home
  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research and Development »
    « Back
    • Drug Development Pipeline
    • Investigational Drug Candidates
    • Diseases and Conditions
    • Clinical Trials
    • Drug Discovery
    • Expanded Access
    • Investigator Initiated Studies
    • Publications
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Scientist Development Program
    • Aclaris Support
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Investor Presentations
    • Investor FAQs
    • Email Alerts
  • Media resources
  • Contact us
  • Home
  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research and Development »
    « Back
    • Drug Development Pipeline
    • Investigational Drug Candidates
    • Diseases and Conditions
    • Clinical Trials
    • Drug Discovery
    • Expanded Access
    • Investigator Initiated Studies
    • Publications
  • Partnerships
  • Careers
  • Citizenship »
    « Back
    • Scientist Development Program
    • Aclaris Support
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Investor Presentations
    • Investor FAQs
    • Email Alerts
  • Drug Development Pipeline
  • Investigational Drug Candidates
  • Diseases and Conditions
  • Clinical Trials
  • Drug Discovery
  • Expanded Access
  • Investigator Initiated Studies
  • Publications

Posters and publications

MK2 pathway inhibitor

Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138 »

Aparna Kaul, Heidi Hope, Canxin Xu, Rakesh Basavalingappa, Sara K. Binz, Chad Boily, Zachary Bradley, David Burt, Catherine Emanuel, Jacob Fairchild, Sarah Egan, Anne Hildebrand, Victoria Howell, Huiyan Huang, Emma Huff, Abbygail Iken, Stephanie Knapik, Melissa Lawrence, Huawen Lin, Jessea Wenjie Lu, Jonathan Mattingly, Dean McGraw, Nancy McGraw, Stephen Mnich, William Morton, Robert Ortmann, Tyler Piccinni-Ash, Rafael Saer, Cristiane Secca da Silva, Loreen Stillwell, William Taylor, Elizabeth Warner, Ann Wrightstone, E. Jon Jacobsen, David R. Anderson, Joseph Monahan

JAK inhibitors

Molecular and Clinical Effects of oral ATI-2138, an ITK/JAK3 inhibitor, in Moderate to Severe Atopic Dermatitis: Sub-study of a Phase 2a Open-Label, Single-Arm Trial »

Jessica Beaziz-Tordjman, Ester Del Duca, Jerry Zhou, Jacob Fiedler, Yeriel Estrada, Joel Correa da Rosa, Juliana Pulsinelli, Digpal Gour Singh, Ragasruthi Metukuru, Joseph Monahan, Aparna Kaul, Ajay Aggarwal, Emma Guttman-Yassky. European Academy of Dermatology and Venereology, September 17, 2025.

    • Terms of use
    • Privacy policy
    • Contact us
    • Fraudulent Activity Notice
    © 2026 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.
      Click to open link